

Birgitt Schüle, MD
Christie Byrne, BS
Linda Rees, MBChB,
MPH
J. William Langston, MD

Neurol Genet
2015;1:e31; doi: 10.1212/
NXG.0000000000000031

IS PARKIN PARKINSONISM A CANCER PREDISPOSITION SYNDROME?

OPEN

Mutations in the *PARKIN* gene (chromosome 6q25-27) were first described in 1998 in families with “juvenile” autosomal recessive parkinsonism. More than 180 causative variants in the *PARKIN* gene have been identified; point mutations and copy number variants (i.e., exon deletions or duplications) occur at nearly equal frequencies.¹ *PARKIN* is one of the largest genes in the human genome (1.3 Mb) and contains a chromosomal fragile site (CFS) FRA6E (6q26) between exons 2 and 8. This is of interest regarding the etiology of cancer because CFSs are prone to spontaneous breaks leading to chromosome alterations. Therefore, it is not surprising that *PARKIN* mutations have also been found in various cancer cell lines and primary tumors.^{2,3} Mutations in *PARKIN* show decreased PARKIN E3 ligase function with resultant accumulation of cyclin E, creating the potential for mitotic instability in dividing cells.

Because the same *PARKIN* gene mutations that lead to early-onset parkinsonism are also found in numerous cancer types, particularly glioblastoma multiforme (GBM),³ it is surprising that *PARKIN* mutations rarely result in both parkinsonism and GBM. This report describes such a patient with compound heterozygous mutations in *PARKIN*, early-onset parkinsonism, and GBM.

Methods. The patient was the oldest sibling of 5 brothers from family Ph and was a carrier of 2 causative mutations in the *PARKIN* gene: NM_004562.2 (*PARKIN*) [c.337_376del40]; [118 kb, exon 6 duplication]. Two of his younger brothers were also compound heterozygous, and his parents and paternal grandmother were carriers of 1 mutated allele.⁴

At 44 years of age, the patient began experiencing parkinsonian symptoms, which started with a rest tremor in the right leg and leg dystonia. He had a good response to dopamine agonists. At age 46, CT and MRI head scans revealed 2 masses in the left temporal lobe. He underwent subtotal resection of the temporal lobe masses followed by radiation and chemotherapy. Tumor histology was GBM. Six months after surgery, there was recurrence of the tumor, and the patient died 14 months after surgery. At autopsy, there was a 1.5-inch-diameter tumor located within the left temporal lobe. Histologically, the

tumor was a typical infiltrating glioblastoma with pleomorphic dedifferentiated astrocytes and areas of necrosis with “pseudopalisading” cells. It infiltrated and obscured the nucleus basalis of Meynert. Additional pathology of note included severe nerve cell loss and gliosis in the substantia nigra but no Lewy bodies or Alzheimer pathology. The locus coeruleus had no definite nerve cell loss, but slight nerve cell loss and gliosis was seen in the dorsal motor nucleus of the vagus nerve.


Discussion. Germ-line mutations in the *PARKIN* gene and GBM in the same patient is extremely rare. GBM has an incidence of 2–3 per 100,000 adults per year and is a primary intracranial tumor of astrocytic origin. The prognosis of GBM is typically very poor, with a median survival of 11–15 months.⁵

Given the rarity of *PARKIN* mutations and GBM, their concomitant occurrence in a single individual may well be more than a coincidence. In general, the etiopathogenesis of most cancer is based on the 2-hit or multiple-hit hypothesis. In the case of patients with parkinsonism with *PARKIN* mutations, they already carry the first hit in every cell (figure). A second hit due to environmental influences (e.g., radiation, toxicants) can then lead to cancer such as ovarian cancer, hepatocellular carcinoma, breast cancer, colon cancer, and GBM.^{2,3} This concept is well described for cancer predisposition syndromes, i.e., breast cancer (*BRCA1* and *BRCA2* genes) and familial adenomatous polyposis (*APC* gene), in which an inherited genetic variant that is present in every cell of the human body combined with an acquired sporadic mutation induces tumor formation.


Future clinical genetic studies are needed to determine whether there is indeed an increased risk for development of malignancies in *PARKIN* carriers. Although there are epidemiologic studies that suggest a lower risk for cancer in patients with neurodegenerative diseases,⁶ an increased cancer risk has been reported for *LRRK2* parkinsonism,⁷ and several cohort studies are being conducted to further understand the causal relationship between cell death in Parkinson disease and uncontrolled cell growth in cancer. This could be a result of impairment in cell cycle regulation, resulting in both neurodegeneration and malignant proliferation.

If additional clinical and experimental evidence proves cause–effect relations for an association between *PARKIN* mutations and cancer, it could open up a new area of

1-hit hypothesis: Familial early-onset parkinsonism



2-hit hypothesis: *PARKIN* cancer predisposition syndrome



Loss of *PARKIN* protein in familial Parkinson disease leads to accumulation of one of its substrates, cyclin E, which has been shown to cause neurodegeneration. We propose that our presented case of glioblastoma multiforme and familial parkinsonism could have developed by acquired somatic mutations in addition to the first hit of *PARKIN* mutations.

cancer research. Furthermore, if larger clinical studies in *PARKIN* mutation carriers confirm an increased cancer risk, families with *PARKIN* parkinsonism will be a critical group to target for cancer screening.

From the Parkinson's Institute and Clinical Center, Sunnyvale, CA. Author contributions: B.S. and J.W.L. designed the study. C.B. and L.R. curated and analyzed the brain autopsies. All authors wrote and edited the manuscript.

Acknowledgment: The authors are indebted to the family for their participation in this study and long-term commitment to help understanding the underlying genetic causes of Parkinson disease. Dr. Lysia Forno, who recently died at age 97, performed the neuropathology evaluation of the brain. She was a dedicated and passionate neuropathologist and inspiration for everyone around her.

Study funding: No targeted funding reported.

Disclosure: Dr. Schüle receives research funds from Life Technologies/ Thermo Fisher, Berg Pharma, Biogen Idec, Parkinson Alliance/ Parkinson's Unity Walk, Michael J. Fox Foundation, and California Institute for Regenerative Medicine (grants #RT2-01965 and #RT2-01880). Ms. Byrne receives research funds from Berg Pharma, Department of Defense (grant #W81XWH-11-1-0310), and the Michael J. Fox Foundation. Dr. Rees receives research support from Berg Pharma, Biogen Idec, the Michael J. Fox Foundation, GE Healthcare, and the Department of Defense (grant #W81XWH-11-1-0310).

Dr. Langston receives research funds from GE Healthcare, Biogen, and Department of Defense (grant #W81XWH-11-1-0310). He serves on the Michael J. Fox Scientific Advisory committee. He is the coeditor of the Journal of Parkinson's Disease. Dr. Langston spends 35% of his time in his clinical practice. Go to Neurology.org/ng for full disclosure forms. The Article Processing Charge was paid by The Parkinson's Institute.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Received August 13, 2015. Accepted in final form September 14, 2015.

Correspondence to Dr. Schüle: bschuele@thepi.org

1. Hedrich K, Eskelson C, Wilmot B, et al. Distribution, type, and origin of Parkin mutations: review and case studies. *Mov Disord* 2004;19:1146–1157.
2. Denison SR, Wang F, Becker NA, et al. Alterations in the common fragile site gene Parkin in ovarian and other cancers. *Oncogene* 2003;22:8370–8378.
3. Veeriah S, Taylor BS, Meng S, et al. Somatic mutations of the Parkinson's disease-associated gene *PARK2* in glioblastoma and other human malignancies. *Nat Genet* 2010;42:77–82.

4. Schüle B, Hatchwell E, Eis PS, Langston JW. Comparative genomic hybridization solves a 14-year-old PARKIN mystery. *Ann Neurol* 2015;78:663–664.
5. Pan IW, Ferguson SD, Lam S. Patient and treatment factors associated with survival among adult glioblastoma patients: a USA population-based study from 2000-2010. *J Clin Neurosci* 2015;22:1575–1581.
6. Driver JA. Inverse association between cancer and neurodegenerative disease: review of the epidemiologic and biological evidence. *Biogerontology* 2014;15:547–557.
7. Agalliu I, San Luciano M, Mirelman A, et al. Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis. *JAMA Neurol* 2015;72:58–65.